*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)! Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF Looking forward to presenting full results at #ESCCongress alongside scottdavidsolomon @PSJhund bayer.com/media/en-us/fi…

Effects of Dapagliflozin in Patients with Membranous Nephropathy looks promising! karger.com/gdz/article/4/…

We are looking for a Statistician for the Epidemiological team in Complications Research Steno diabetes center copenhagen shar.es/ag56iQ

Effects of Dapagliflozin in Patients with Membranous Nephropathy : looking good, but we will need to learn more pubmed.ncbi.nlm.nih.gov/39144475/

Swe the amazing Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD sciencedirect.com/science/articl… Steno Diabetes Center Copenhagen

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial academic.oup.com/eurheartj/arti…

The first simpub from the CTCPR Trials & CIRL team during #ESC2024. The NUDGE-FLU-2 trial results in Nature Medicine lead by Niklas Dyrby Johansen 👇 Electronic nudges for sustained influenza vaccination uptake in older adults (>65): the nationwide randomized NUDGE-FLU-2 trial nature.com/articles/s4159…

Bnefit of semaglutide in heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials sciencedirect.com/science/articl…

See Prof Pratley share Insights from the FLOW Trial | ESC 2024 youtu.be/jCmyx8_4nlk?si… via YouTube

Lovely final slide of the FINEHEART presentation from Muthu Vaduganathan dedicated to the late Professor George Bakris #ESCCongress

See the FINE-HEART all phase 3 studies with finerenone compiled rdcu.be/dSC7n

Bridging T2D and T1D in CKD treatment “To generation zero in T1D” EASD #Easd2024 Peter Rossing

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial | ⁦Nature Medicine⁩ Spiro was often discontinued and no effect on outcome nature.com/articles/s4159…

Our latest NUDGE trial just published in JAMA 👇 Led by the brilliant Niklas Dyrby Johansen, in collaboration with amazing colleagues from Statens Serum Institut Harvard Medical School Region Midtjylland and many more. CTCPR Trials & CIRL continues to provide important evidence regarding how we can improve public health

Severely increased albuminuria at screening is a powerful criterion for selecting persons with T1D at high risk of kidney function decline. pubmed.ncbi.nlm.nih.gov/39423023/

Endothelial dysfunction markers syndecan-1 and thrombomodulin are associated with higher albuminuria levels in t2d without CVD pubmed.ncbi.nlm.nih.gov/39405782/

"We do much more complicated things, we use much more dangerous drugs for other conditions that don't deliver like this" "And if you don't do it, you're likely to become obsolete... because someone else will" Professor Tuttle with a #kidneywk call to arms 🔥🔥🔥 #kidneycompass

No effects of probiotics and fibers on markers of nephropathy, inflammation and intestinal barrier in T1D during a 12w study sciencedirect.com/science/articl… Steno Diabetes Center Copenhagen Elisabeth Buur Stougaard

see the effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study - …ibrary-wiley-com.ep.fjernadgang.kb.dk/doi/full/10.11…